Thus, considering the remarkable immunosuppressive effect of ICOS, an anti-ICOS antagonist might be more appropriate in glioma; however, this requires a further in-depth understanding of the mechanism of ICOS. The gene discussed is ICOS; the disease is central nervous system cancer.